Article Details

Refractory Metastatic Melanoma Pipeline Report 2025, with - GlobeNewswire

Retrieved on: 2025-03-20 17:38:37

Tags for this article:

Click the tags to see associated articles and topics

Refractory Metastatic Melanoma Pipeline Report 2025, with - GlobeNewswire. View article details on hiswai:

Excerpt

Phase II include, BioNTech SE. Key Players. BioNTech SE; Y-mAbs Therapeutics; Seagen Inc. Key Products. BNT111; GD2-SADA; SEA-CD40. For more ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo